The estimated Net Worth of Susan Elizabeth Arnold is at least $922 dollars as of 27 February 2020. Susan Arnold owns over 10,846 units of PhaseBio Pharmaceuticals stock worth over $922 and over the last 5 years he sold PHAS stock worth over $0. In addition, he makes $0 as Vice President - Preclinical and Chemistry a Manufacturing and Controls at PhaseBio Pharmaceuticals.
Susan has made over 1 trades of the PhaseBio Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 10,846 units of PHAS stock worth $12,473 on 27 February 2020.
The largest trade he's ever made was exercising 10,846 units of PhaseBio Pharmaceuticals stock on 27 February 2020 worth over $12,473. On average, Susan trades about 1,205 units every 0 days since 2020. As of 27 February 2020 he still owns at least 13,152 units of PhaseBio Pharmaceuticals stock.
You can see the complete history of Susan Arnold stock trades at the bottom of the page.
Dr. Susan Elizabeth Arnold Ph.D. serves as Vice President - Preclinical and Chemistry, Manufacturing and Controls of the Company. serves as Vice President - Preclinical and Chemistry, Manufacturing and Controls of the Company. Dr. Arnold received a B.A. in biology from Holy Family University and an M.S. in cell biology and biotechnology and a Ph.D. in cell and molecular biology from the University of the Sciences in Philadelphia.
Susan Arnold is 45, he's been the Vice President - Preclinical and Chemistry a Manufacturing and Controls of PhaseBio Pharmaceuticals since 2010. There are 17 older and 1 younger executives at PhaseBio Pharmaceuticals. The oldest executive at PhaseBio Pharmaceuticals, Inc. is Nancy Hutson, 70, who is the Independent Director.
Susan's mailing address filed with the SEC is C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PARKWAY, SUITE 30, MALVERN, PA, 19355.
Over the last 6 years, insiders at PhaseBio Pharmaceuticals have traded over $361,083 worth of PhaseBio Pharmaceuticals stock and bought 24,000 units worth $81,960 . The most active insiders traders include Clay Thorp, Enterprise Associates 13 Lp... a Nancy J Hutson. On average, PhaseBio Pharmaceuticals executives and independent directors trade stock every 52 days with the average trade being worth of $5,138. The most recent stock trade was executed by Clay Thorp on 19 May 2023, trading 3,750 units of PHAS stock currently worth $263.
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.
PhaseBio Pharmaceuticals executives and other stock owners filed with the SEC include: